Patents Assigned to PRINDEX S.R.L.
  • Diagnosis and therapy of multiple sclerosis
    Patent number: 11505592
    Abstract: The serotonin receptor 5HT2A (5HT2aR) and membrane NADPH oxidases (NOX enzymes) are found to be a target of autoantibodies present in Multiple Sclerosis patients. The present invention refers to peptides comprised in the extracellular regions of the human 5HT2aR and/or NOXs for diagnosis and therapy of Multiple Sclerosis.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: November 22, 2022
    Assignee: PRINDEX S.R.L.
    Inventors: Roberto Paterno, Mariarosaria Santillo, Vittorio Enrico Avvedimento, Luigi Michele Pavone
  • Diagnosis and therapy of Multiple Sclerosis
    Publication number: 20200308251
    Abstract: The serotonin receptor 5HT2A (5HT2aR) and membrane NADPH oxidases (NOX enzymes) are found to be a target of autoantibodies present in Multiple Sclerosis patients. The present invention refers to peptides comprised in the extracellular regions of the human 5HT2aR and/or NOXs for diagnosis and therapy of Multiple Sclerosis.
    Type: Application
    Filed: April 24, 2020
    Publication date: October 1, 2020
    Applicant: PRINDEX S.R.L
    Inventors: Roberto Paterno, Mariarosaria Santillo, Vittorio Enrico Avvedimento, Luigi Michele Pavone
  • Diagnosis and therapy of multiple sclerosis
    Patent number: 10633427
    Abstract: The serotonin receptor 5HT2A (5HT2aR) and membrane NADPH oxidases (NOX enzymes) are found to be a target of autoantibodies present in Multiple Sclerosis patients. The present invention refers to peptides comprised in the extracellular regions of the human 5HT2aR and/or NOXs for diagnosis and therapy of Multiple Sclerosis.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: April 28, 2020
    Assignee: PRINDEX S.R.L.
    Inventors: Roberto Paterno, Mariarosaria Santillo, Vittorio Enrico Avvedimento, Luigi Michele Pavone